SCYNEXIS (SCYX) Competitors

$0.66 -0.03 (-4.14%)

Closing price 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.12%)

As of 07:58 PM Eastern

SCYX vs. EQ, RANI, DERM, GNLX, and AARD

Should you buy SCYNEXIS stock or one of its competitors? MarketBeat compares SCYNEXIS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SCYNEXIS include Equillium (EQ), Rani Therapeutics (RANI), Journey Medical (DERM), Genelux (GNLX), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry.

How does SCYNEXIS compare to Equillium?

SCYNEXIS (NASDAQ:SCYX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

SCYNEXIS has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Equillium has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

In the previous week, SCYNEXIS and SCYNEXIS both had 4 articles in the media. SCYNEXIS's average media sentiment score of 0.14 beat Equillium's score of -0.75 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 4.9% of SCYNEXIS shares are owned by company insiders. Comparatively, 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Equillium has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Equillium	N/A	-61.43%	-53.72%

SCYNEXIS has higher earnings, but lower revenue than Equillium. Equillium is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	1.42	-$8.61M	-$0.48	N/A
Equillium	$41.10M	2.72	-$22.40M	-$0.32	N/A

SCYNEXIS presently has a consensus price target of $3.00, indicating a potential upside of 356.76%. Equillium has a consensus price target of $7.67, indicating a potential upside of 334.37%. Given SCYNEXIS's higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Equillium beats SCYNEXIS on 9 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rani Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

In the previous week, Rani Therapeutics had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 5 mentions for Rani Therapeutics and 4 mentions for SCYNEXIS. Rani Therapeutics' average media sentiment score of 0.27 beat SCYNEXIS's score of 0.14 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rani Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 889.37%. SCYNEXIS has a consensus target price of $3.00, indicating a potential upside of 356.76%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Rani Therapeutics is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SCYNEXIS has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	67.11	-$29.67M	-$0.41	N/A
SCYNEXIS	$20.60M	1.42	-$8.61M	-$0.48	N/A

Rani Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Summary

Rani Therapeutics beats SCYNEXIS on 9 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

SCYNEXIS has lower revenue, but higher earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.72	-$11.43M	-$0.37	N/A
SCYNEXIS	$20.60M	1.42	-$8.61M	-$0.48	N/A

In the previous week, Journey Medical had 16 more articles in the media than SCYNEXIS. MarketBeat recorded 20 mentions for Journey Medical and 4 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.14 beat Journey Medical's score of -0.51 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	1 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Journey Medical currently has a consensus price target of $13.00, indicating a potential upside of 111.38%. SCYNEXIS has a consensus price target of $3.00, indicating a potential upside of 356.76%. Given SCYNEXIS's higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Journey Medical has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Journey Medical has a net margin of -14.82% compared to SCYNEXIS's net margin of -41.79%. Journey Medical's return on equity of -35.57% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Summary

Journey Medical beats SCYNEXIS on 10 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to Genelux?

SCYNEXIS (NASDAQ:SCYX) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

SCYNEXIS presently has a consensus price target of $3.00, suggesting a potential upside of 356.76%. Genelux has a consensus price target of $18.00, suggesting a potential upside of 542.86%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, SCYNEXIS had 4 more articles in the media than Genelux. MarketBeat recorded 4 mentions for SCYNEXIS and 0 mentions for Genelux. SCYNEXIS's average media sentiment score of 0.14 beat Genelux's score of -0.45 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Overall Sentiment
SCYNEXIS	Neutral
Genelux	Neutral

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SCYNEXIS has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Genelux has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

SCYNEXIS has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	1.42	-$8.61M	-$0.48	N/A
Genelux	$10K	12,555.20	-$32.15M	-$0.85	N/A

Genelux has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Genelux	N/A	-174.55%	-123.65%

Summary

SCYNEXIS beats Genelux on 10 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

54.4% of SCYNEXIS shares are owned by institutional investors. 4.9% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SCYNEXIS has higher revenue and earnings than Aardvark Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
SCYNEXIS	$20.60M	1.42	-$8.61M	-$0.48	N/A

Aardvark Therapeutics presently has a consensus target price of $19.70, indicating a potential upside of 350.80%. SCYNEXIS has a consensus target price of $3.00, indicating a potential upside of 356.76%. Given SCYNEXIS's higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aardvark Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Aardvark Therapeutics has a beta of 5.11, indicating that its stock price is 411% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 8 more articles in the media than SCYNEXIS. MarketBeat recorded 12 mentions for Aardvark Therapeutics and 4 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.14 beat Aardvark Therapeutics' score of -0.07 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

SCYNEXIS beats Aardvark Therapeutics on 9 of the 16 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCYX vs. The Competition

Export

Metric	SCYNEXIS	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.60M	$2.99B	$6.25B	$12.23B
Dividend Yield	N/A	1.96%	2.80%	5.32%
P/E Ratio	-1.37	17.04	20.79	25.05
Price / Sales	1.42	251.21	531.21	72.69
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	0.71	4.39	9.81	6.83
Net Income	-$8.61M	$74.99M	$3.55B	$335.69M
7 Day Performance	-15.79%	-4.89%	-2.07%	-2.03%
1 Month Performance	-40.83%	-8.30%	-3.90%	-1.90%
1 Year Performance	-21.06%	28.66%	29.39%	27.36%

SCYNEXIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCYX SCYNEXIS	2.0826 of 5 stars	$0.66 -4.1%	$3.00 +356.8%	-13.3%	$30.60M	$20.60M	N/A	60	Upcoming Earnings Analyst Downgrade Short Interest Increase
EQ Equillium	2.4929 of 5 stars	$2.20 -2.4%	$7.67 +249.3%	+392.0%	$138.79M	$41.10M	N/A	40	Earnings Report Analyst Downgrade
RANI Rani Therapeutics	2.9533 of 5 stars	$1.11 +3.3%	$7.80 +605.9%	+51.8%	$136.68M	$1.63M	N/A	110	Earnings Report Analyst Upgrade
DERM Journey Medical	2.2281 of 5 stars	$4.97 -0.7%	$13.00 +161.8%	-9.8%	$135.72M	$61.86M	N/A	90	Earnings Report Analyst Revision
GNLX Genelux	1.978 of 5 stars	$2.98 +2.6%	$18.00 +505.0%	+14.9%	$133.40M	$10K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCYX) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SCYNEXIS (SCYX) Competitors

SCYX vs. EQ, RANI, DERM, GNLX, and AARD

How does SCYNEXIS compare to Equillium?

Summary

How does SCYNEXIS compare to Rani Therapeutics?

Summary

How does SCYNEXIS compare to Journey Medical?

Summary

How does SCYNEXIS compare to Genelux?

Summary

How does SCYNEXIS compare to Aardvark Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SCYNEXIS (SCYX) Competitors

SCYX vs. EQ, RANI, DERM, GNLX, and AARD

How does SCYNEXIS compare to Equillium?

Which has more volatility and risk, SCYX or EQ?

Does the media favor SCYX or EQ?

Do institutionals and insiders have more ownership in SCYX or EQ?

Is SCYX or EQ more profitable?

Which has stronger earnings and valuation, SCYX or EQ?

Do analysts rate SCYX or EQ?

Summary

How does SCYNEXIS compare to Rani Therapeutics?

Do insiders and institutionals have more ownership in RANI or SCYX?

Which has more risk & volatility, RANI or SCYX?

Does the media favor RANI or SCYX?

Do analysts rate RANI or SCYX?

Which has higher valuation and earnings, RANI or SCYX?

Is RANI or SCYX more profitable?

Summary

How does SCYNEXIS compare to Journey Medical?

Which has stronger valuation and earnings, DERM or SCYX?

Does the media refer more to DERM or SCYX?

Do insiders & institutionals hold more shares of DERM or SCYX?

Do analysts prefer DERM or SCYX?

Which has more volatility and risk, DERM or SCYX?

Is DERM or SCYX more profitable?

Summary

How does SCYNEXIS compare to Genelux?

Do analysts recommend SCYX or GNLX?

Does the media prefer SCYX or GNLX?

Do insiders and institutionals hold more shares of SCYX or GNLX?

Which has more risk & volatility, SCYX or GNLX?

Which has preferable valuation and earnings, SCYX or GNLX?

Is SCYX or GNLX more profitable?

Summary

How does SCYNEXIS compare to Aardvark Therapeutics?

Do insiders & institutionals have more ownership in AARD or SCYX?

Which has higher earnings & valuation, AARD or SCYX?

Do analysts recommend AARD or SCYX?

Is AARD or SCYX more profitable?

Which has more risk and volatility, AARD or SCYX?

Does the media refer more to AARD or SCYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools